At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Pomalidomide +1 moredrug
Likely dose
Pomalidomide 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Single-arm, Open-label Study in Japan to Evaluate the Efficacy and Safety of Pomalidomide (CC-4047) in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Pomalidomide and Dexamethasone for Multiple Myeloma. Completed, enrolled 36 participants across 14 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of pomalidomide in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartDec 2013
First PostedDec 2013
Primary CompletionSep 2014
Study CompletionSep 2015
TodayJul 2026
First PostedDec 13, 2013
Enrollment StartDec 1, 2013
Primary CompletionSep 1, 2014
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.6 years ago
Interventions
Pomalidomidedrug
4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle
Dexamethasonedrug
40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle